BioCentury
ARTICLE | Clinical News

Zadaxin thymosin alpha 1 immunomodulator regulatory update

December 11, 2000 8:00 AM UTC

SCLN received notice of allowance for a European patent covering the use of Zadaxin to treat hepatitis C virus (HCV) infection in non-responders, defined as patients who have been treated for one year...